跳至主要内容
临床试验/ACTRN12614001224617
ACTRN12614001224617进行中(未招募)4 期

A randomized clinical trial to study whether telbivudine can decrease the hepatitis B virus reactivation in patients with hepatocellular carcinoma and HBV-DNA < 2000 IU/ml after liver resection.

ZHOU Wei-ping0 个研究点目标入组 200 人开始时间: 2014年11月21日最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • 1) Age 18 to 70 years;
  • 2) Positive test for Hepatitis B surface antigen (HBsAg)
  • 3) Serum hepatitis B virus-deoxyribonucleic acid (HBV-DNA) level lower than 2000IU/ml;
  • 4) Serum ALT levels are below the upper limit of normal (ULN);
  • 5) Resectable tumour with Barcelona Clinic Liver Cancer (BCLA) stage 0 or A;
  • 6)Good liver function with Child-Pugh Class A, with no history of encephalopathy, ascites refractory to diuretics, esophago-gastricvaricesor variceal bleeding;
  • 7) Good kidney function (a serum creatinine level < 133 umol/L and creatinine clearance >60 ml/min);
  • 8) The preoperative diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL).

排除标准

  • 1)Positive tests for antibody to hepatitis C virus (HCV-Ab) or human immunodeficiency virus;
  • 2)extrahepatic metastasis;
  • 3)radiologic evidence of invasion into the major portal/hepatic venous branches;
  • 4)previous treatment of HCC;
  • 5)previous history of antiviral therapy;
  • 6)previous history of cancer and chemotherapy
  • 7)previous history of immunosuppressive therapy

研究者

发起方
ZHOU Wei-ping

相似试验